Commission file number: 0-18892

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF

THE SECURITIES EXCHANGE ACT OF 1934

For ~~May/~~17 June 2005

MAYNE GROUP LIMITED

(Translation of Registrant’s Name into English)

Mayne Group House

21/390 St Kilda Road

Melbourne, Victoria 3004

Australia

(Address of Principal Executive Offices)

(Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.)

Form 20-F X Form 40-F

(Indicate by check mark whether the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.)

Yes No X .

(If “Yes is marked indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- .)

Media Releases / ASX Announcements

Exhibit 1 – ~~Share~~Update ~~buy-back~~regarding proposed demerger

Exhibit 2 - Mayne announces Board appointments

EXHIBIT 1

12ASX ~~May~~and ~~2005~~Media Release

~~Company~~17 ~~Announcements~~June ~~Office~~2005

~~Australian~~UPDATE ~~Stock~~REGARDING ~~Exchange~~PROPOSED DEMERGER

~~Level~~Mayne Group Limited (Mayne) advised today that based on further work conducted as part of the demerger review process announced on 4 May 2005, the Board has determined to proceed with a demerger involving separate Australian listings of its global injectable pharmaceutical business (Mayne Pharma) and its domestic healthcare businesses (Mayne Diagnostic Services, Mayne Pharmacy and Mayne Consumer Products).

20Mayne’s Chairman, ~~Bridge~~Mr ~~Street~~Peter Willcox said, “The work completed so far makes us confident that a demerger provides the best opportunity to deliver increased value for shareholders.”

~~Sydney~~“We ~~NSW~~believe ~~2000~~listing the two demerged companies in Australia will meet their strategic and capital requirements without unduly disturbing their operations,” he said.

~~Dear~~“The ~~Sir~~separation of Mayne’s global injectable pharmaceutical business from the domestic healthcare businesses will enable each of the businesses to focus on their core activities and more effectively implement their distinctive strategies.

~~Re:~~“Importantly, ~~Share~~investors ~~buy-back~~will have the ability to invest directly in either or both companies based on the investment characteristics that best meet their objectives.”

Mayne’s Group ~~Limited~~Managing ~~announced~~Director onand 4Chief ~~May~~Executive ~~2005~~Officer, ~~that~~Mr itStuart isJames ~~undertaking~~said, a“Mayne ~~strategic~~Pharma ~~review~~is togrowth ~~assess~~oriented ~~the merits of a demerger involving separate listings of its pharmaceutical~~ and ~~healthcare businesses and~~, ifconsistent awith ~~demerger~~its isglobal ~~undertaken~~peers, ~~the~~will ~~optimal~~reinvest ~~configuration~~a ofsignificant ~~the~~portion ~~listed entities. In light~~ of ~~this~~its ~~review,~~cash flows ~~based on legal advice the company has decided~~ to ~~suspend~~continue ~~purchases under~~ its ~~on-market~~ ~~share~~growth ~~buy-back~~trajectory ~~announced~~in onfuture ~~8 March 2005 until either the strategic review is completed or notice is given that the buy-back is to be resumed~~years.

~~For~~“Mayne’s domestic ~~the~~businesses ~~avoidance of doubt~~have, ~~the Appendix 3F Final Share Buy-Back Notice filed~~ on ~~23 March 2005 related to~~ the ~~on-market~~other ~~buy-back~~hand, ~~programme~~historically ~~announced~~generated onstrong 1operating ~~March~~cash ~~2004~~flows ~~(as amended~~to onsupport 22dividend ~~March 2004) and did not affect the on-market share buy-back announced on 8 March 2005~~payments.”

~~Yours~~As ~~faithfully~~another important step in the demerger process, Mayne announced today that following completion of the demerger, Mr Peter Willcox will become Chairman of Mayne Pharma and Mr Paul McClintock will become the Chairman of Mayne’s domestic healthcare businesses. Recognising the importance of a smooth transition process for this key role, Mr McClintock has been appointed Deputy Chairman of Mayne. Mayne will benefit from Mr McClintock’s extensive healthcare and government relations experience in Australia.

~~Mayne~~In ~~Group~~conclusion ~~Limited~~Mr /Willcox said, “Our Board is convinced that a demerger is the best strategy for delivering value for shareholders, and given this view, we are re-iterating that it is not our intention to sell any of Mayne’s~~/Timothy~~ Abusinesses. ~~Paine~~Our ~~Timothy~~focus A.is ~~Paine~~on ~~Company~~ensuring ~~Secretary~~the demerger process is rigorous and efficient.

~~EXHIBIT~~“Subject 2to completion of the necessary steps to effect a demerger, we currently expect completion this calendar year.”

~~Media~~Morgan Stanley and ~~ASX~~Clayton ~~Release~~Utz have been appointed to advise Mayne in relation to the demerger. KPMG have been appointed to provide tax advice.

8EXHIBIT ~~June~~1 ~~2005~~

Mayne announces Board appointments

Mayne Group Limited (ASX:MAY) today announced the appointment of two new non-executive Directors to the Mayne Board, Mr James (Jim) Hall and Mr Paul McClintock.

Mr Hall has more than 35 years in senior financial management roles. Most recently Mr Hall was Executive Director of Finance at Orica Limited, a role he held since January 2002. In his time at Orica, Mr Hall was a key member of the senior management team, during a period when the financial performance of Orica’s established businesses improved significantly. Retiring from Orica in April 2005, Mr Hall was briefly a Director of Affinity Health as it prepared for an ASX listing. He is currently a Director of Qenos Holdings Pty Ltd and will join the Board of Alesco Corporation Limited on 1 July 2005.

Prior to joining Orica, Mr Hall was Vice President, Group Accounting and Controller at BHP Billiton. In his 32 years at BHP, Mr Hall held a range of senior financial management roles. Mr Hall had significant experience in both merger and demerger activities during his time at BHP.

Mr McClintock is a qualified lawyer, with an extensive career in corporate advisory and government. Since 1985 he has been a principal of the private investment banking firm, McClintock Associates, apart from 2000-2003 when he served as Secretary to Cabinet and Head of the Cabinet Policy Unit, reporting directly to the Prime Minister.

Mr McClintock has a strong background in health, serving as Chairman of Affinity Health from January 2004 to April 2005. He is currently a Director of ANZAC Medical Research Centre and a Commissioner of the Health Insurance Commission. Other directorships currently held by Mr McClintock are Chairman of Thales Australia Group, Director of Perpetual Trustees Australia Limited and Director of Macquarie Infrastructure Group.

Mayne’s Chairman, Mr Peter Willcox, said he was delighted to welcome Mr Hall and Mr McClintock to the Board.

“The demerger review process is progressing well and the Board’s appointment of two additional non-executive Directors is an important development in the process.

“Both Directors will be invaluable to Mayne during the demerger review and in the next phase of development of the company. In particular, both Mr Hall and Mr McClintock have experience in the rigorous process of preparing a company for listing through their recent directorships at Affinity Health,” he said.

Mr Hall’s and Mr McClintock’s appointments are effective today, 8 June 2005, and they will both stand for election at the 2005 Annual General Meeting. Should the demerger proceed, it is anticipated that Mr Hall and Mr McClintock will each serve as a Director of one of the demerged entities.

EXHIBIT 2

About Mayne Group Limited

Mayne Group Limited is ~~listed~~a onleading ~~the~~ Australian-based ~~Stock~~healthcare ~~Exchange~~company ~~and~~with ~~has~~revenues ~~businesses~~ in ~~international~~excess ~~specialty pharmaceuticals (the manufacture~~ of ~~injectable~~$A ~~and~~4 ~~oral pharmaceuticals~~billion ~~for~~in ~~distribution~~its to2004 ~~more~~financial ~~than 50 countries), diagnostic services (pathology, diagnostic imaging and medical centres), pharmacy, and health-related consumer products~~year.

~~oooo0000oooo~~Mayne Group is comprised of several leading Australian healthcare businesses that are well positioned to grow in future years. Mayne Diagnostic Services operates the second largest pathology and diagnostic imaging networks in Australia. Mayne Pharmacy distributes pharmaceutical and over the counter products to retail pharmacies across Australia and provides a range of professional services that assist pharmacists in better managing their businesses. Its leading pharmacy retail banners include Terry White Chemists®, Chemmart® and The Medicine Shoppe®. Mayne Consumer Products is Australia’s leading provider of vitamin and mineral supplements across the grocery and pharmacy retail channels with the following brands: Nature’s Own™, Cenovis®, Natural Nutrition™, BioOrganics™, and Golden Glow®.

Media enquiries		Investor enquiries
Jason Thomas		Caroline Ingham
Communications Manager		Investor Relations Manager
Ph: +61 3 9868 0706		Ph: +61 3 9868 0894
Mb: +61 421 341 709		Mb: +61 419 526 355

Mayne Pharma has grown to be a market leader for generic, injectable oncology drugs in Western Europe, Canada and Australia and has established businesses in the United States, the Middle East and Africa, and Asia. Mayne Pharma’s products are marketed in more than 50 countries across five continents. This broad geographic sales, marketing and regulatory platform in generic, injectable medicines is a valuable asset and Mayne Pharma’s emphasis on the cytotoxic oncology (anti-cancer) market segment benefits from higher barriers to entry and lower competition than in generic, oral pharmaceuticals.

Media and investor enquiries

Larry Hamson

General Manager Corporate Relations

Ph: +61 3 9868 0380

Mb: +61 407 335 907

Note

This announcement does not constitute an offer or sale of securities in the United States or any other jurisdiction. Securities may not be offered or sold in the United States unless pursuant to a transaction that is registered under the US Securities Act of 1933 or pursuant to an applicable exemption from the registration requirements thereof.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


MAYNE GROUP LIMITED

By:		/s/ Timothy Paine
Name:		Timothy Paine
Title:		Company Secretary

Date: 817 June 2005

Filing Compare · MAYNE GROUP LTD